Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11040956 Synthesis of omecamtiv mecarbil

Patent 11040956 was granted and assigned to Amgen on June, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Amgen

Current Assignee

Amgen

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11040956

Date of Patent

June 22, 2021

Patent Application Number

16607940

Date Filed

June 29, 2018

Patent Citations Received

‌

US Patent 11986474 Methods for treating heart failure by administering cardiac sarcomere activators

‌

US Patent 11472773 Salt of omecamtiv mecarbil and process for preparing salt

‌

US Patent 11931358 Methods of treating heart failure with cardiac sarcomere activators

‌

US Patent 11958809 Salt of omecamtiv mecarbil and process for preparing salt

‌

US Patent 11465969 Salts and crystal forms of omecamtiv mecarbil

‌

US Patent 11254658 Bisamide sarcomere activating compounds and uses thereof

‌

US Patent 11702380 Synthesis of omecamtiv mecarbil

‌

US Patent 11299479 Bisamide sarcomere activating compounds and uses thereof

...

Patent Primary Examiner

‌

Bruck Kifle

Patent abstract

Provided herein is a synthesis for omecamtiv mecarbil dihydrochloride hydrate and various intermediates. (I)

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11040956 Synthesis of omecamtiv mecarbil

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API